Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
353 articles about Travere Therapeutics
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Travere Therapeutics, Inc. reported its fourth quarter and full year 2021 financial results and provided a corporate update.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 14, 2022
2/14/2022
Travere Therapeutics, Inc. announced that on February 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 70,600 shares of its common stock to seven new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 45,600 shares of its common stock.
-
Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
2/10/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close of the U.S. financial markets.
-
Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
Travere Therapeutics, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. ET.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 12, 2022
1/12/2022
Travere Therapeutics, Inc. announced that on January 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 42,000 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 33,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 9,000 shares of its common stock.
-
Travere Therapeutics Provides Corporate Update and 2022 Outlook
1/10/2022
Travere Therapeutics announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million.
-
Movers & Shakers, Jan. 7
1/7/2022
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers. -
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
1/4/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
12/15/2021
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 14, 2021
12/14/2021
Travere Therapeutics, Inc. announced that on December 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 71,350 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 58,500 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 12,850 shares of its common stock.
-
Travere Therapeutics to Present at Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Travere Therapeutics, Inc. announced that management will present a Company overview at the following upcoming virtual investor conferences in November.
-
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
11/2/2021
Travere Therapeutics, Inc. announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy, at the American Society of Nephrology Kidney Week 2021.
-
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
10/28/2021
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2021 financial results and provided a corporate update.
-
Travere Therapeutics to Report Third Quarter 2021 Financial Results
10/14/2021
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/13/2021
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants
-
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
9/16/2021
Vifor Pharma Group and Travere Therapeutics, Inc. announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand.
-
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
9/15/2021
Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand.
-
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of DirectorsMs. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board
9/14/2021
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately.